Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

The Lancet Oncology
Fabio ConfortiAron Goldhirsch

Abstract

Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments. We did a systematic review and meta-analysis to assess the heterogeneity of immune checkpoint inhibitor efficacy between men and women. We systematically searched PubMed, MEDLINE, Embase, and Scopus, from database inception to Nov 30, 2017, for randomised controlled trials of immune checkpoint inhibitors (inhibitors of PD-1, CTLA-4, or both) that had available hazard ratios (HRs) for death according to patients' sex. We also reviewed abstracts and presentations from all major conference proceedings. We excluded non-randomised trials and considered only papers published in English. The primary endpoint was to assess the difference in efficacy of immune checkpoint inhibitors between men and women, measured in terms of the difference in overall survival log(HR) reported in male and female study participants. We calculated the pooled overall survival HR and 95% CI in men and women using a random-effects model, and assessed the heterogeneity between the two estimates using an interaction test. Of 7133 studies identified in our search, there ...Continue Reading

Citations

Oct 31, 2018·Journal of Cancer Research and Clinical Oncology·Fabian FinkelmeierOliver Waidmann
Feb 5, 2019·Cardiovascular Research·Jiun-Ruey HuJavid Moslehi
Jan 31, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F ConfortiA Goldhirsch
Jul 13, 2019·Future Oncology·Jarrett J FailingRoxana S Dronca
Jul 31, 2019·Immunotherapy·Maria A VelezLaura P Stabile
Nov 7, 2019·Nature·Cara TannenbaumLonda Schiebinger
Mar 5, 2020·Asia-Pacific Journal of Clinical Oncology·Yingxian Liu, Wei Wu
Apr 11, 2020·Journal for Immunotherapy of Cancer·Teilo H SchallerJohn H Sampson
Aug 24, 2019·Veterinary and Comparative Oncology·Liliana Endo-MunozNicholas A Saunders
May 14, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Huan ChenXueyan Cao
Feb 15, 2020·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M T FerrettiR Schmidt
May 18, 2020·Medical Physics·Sunan CuiIssam El Naqa
Apr 5, 2020·Clinical and Experimental Pharmacology & Physiology·Dong WangShengzhi Xie
Jun 26, 2020·JCO Oncology Practice·Zimu Gong, Yinghong Wang
May 27, 2020·British Journal of Cancer·Anita L RayKatherine T Morris
May 15, 2020·Melanoma Research·Rosalynn R Z ConicBrian R Gastman
Jul 11, 2020·Cancers·Maria BellenghiGianfranco Mattia
Jul 1, 2020·Carcinogenesis·Shanshan DengSeyed Javad Moghaddam
Sep 2, 2020·Japanese Journal of Clinical Oncology·Toshio KuboKatsuyuki Kiura
May 21, 2019·Journal of the National Cancer Institute·Leandro Machado ColliStephen J Chanock
Jun 6, 2019·The New England Journal of Medicine·Caroline RobertGeorgina V Long
May 21, 2019·Journal of the National Cancer Institute·Fabio ConfortiAron Goldhirsch
Sep 7, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shixiang WangXue-Song Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.